Immunovant Stock Options Expiring on 18th of July 2025
| IMVT Stock | USD 28.73 1.57 5.78% |
Immunovant's latest option contracts expiring on 2025-07-18 are carrying combined implied volatility of 0.13 with a put-to-call open interest ratio of 0.0 over 4 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on 2025-07-18. The total put volume is at 86.0, with calls trading at the volume of 86.0. This yields a 0.0 put-to-call volume ratio.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunovant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. Immunovant Current Options Market Mood
Immunovant's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Immunovant Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Volume
Unfortunately, most Immunovant's options investors are not very successful. Immunovant's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Immunovant contract
Base on the Rule 16, the options market is currently suggesting that Immunovant will have an average daily up or down price movement of about 0.008125% per day over the life of the 2025-07-18 option contract. With Immunovant trading at USD 28.73, that is roughly USD 0.002334. If you think that the market is fully incorporating Immunovant's daily price movement you should consider buying Immunovant options at the current volatility level of 0.13%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Immunovant |
Immunovant Total Stockholder Equity
Total Stockholder Equity |
|
Immunovant Corporate Management
| MD MBA | Executive Board | Profile | |
| Jay Stout | Chief Officer | Profile | |
| Mark JD | Chief Secretary | Profile | |
| Julia Butchko | Chief Officer | Profile | |
| Andy Deig | Senior Finance | Profile | |
| Mark Levine | Chief Secretary | Profile | |
| Lauren MBA | Vice Marketing | Profile |
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.